Sign in

You're signed outSign in or to get full access.

Ankush Mahajan

Ankush Mahajan

Research Analyst at Axis Securities

Maharashtra, India

Ankush Mahajan is a Research Analyst at Axis Securities, specializing in fundamental equity research with a focus on the Indian healthcare and cement sectors. He actively covers companies including Healthcare Global Enterprises Ltd., Biocon Ltd., Star Cement, and Global Health Ltd., providing detailed financial analyses and investment recommendations that have led to notable forecast accuracy and robust return targets, such as a forecasted 67% EPS growth for Healthcare Global Enterprises and outperform ratings on multiple sector leaders. With a research career at Axis Securities dating back at least to 2021, Mahajan has built a reputation for analytical depth, regularly featured in Axis Securities’ institutional reports. As a SEBI-registered Research Analyst, he adheres to regulatory standards for financial research disclosure and compliance.

Ankush Mahajan's questions to DR REDDYS LABORATORIES (RDY) leadership

Question · Q4 2024

Ankush Mahajan sought to understand the reason for the sequential decrease in U.S. sales, asking if it was driven by the base business or generic Revlimid. He also requested the full-year EBITDA margin guidance for FY'25.

Answer

CEO Erez Israeli clarified that the sequential decline in U.S. sales was a combination of normal ordering patterns and some price erosion on a few products, not specific to any single product. He did not provide specific guidance for FY'25 but reiterated the company's long-term ambition to maintain a 25% EBITDA margin and 25% ROCE, noting that performance can fluctuate around this target.

Ask follow-up questions

Fintool

Fintool can predict DR REDDYS LABORATORIES logo RDY's earnings beat/miss a week before the call